EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 31 / No 12 (Décembre 2015) Med Sci (Paris), 31 12 (2015) 1109-1114 References
Free Access
Issue
Med Sci (Paris)
Volume 31, Number 12, Décembre 2015
Page(s) 1109 - 1114
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20153112014
Published online 16 December 2015
  1. Joffres M, Shields M, Tremblay MS. Connor Gorber S. Dyslipidemia prevalence, treatment, control and awareness in the Canadian health measures survey. Can J Public Health 2013 ; 104 : 252–257. [Google Scholar]
  2. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005 ; 366 : 1267–1278. [CrossRef] [PubMed] [Google Scholar]
  3. Macedo AF, Taylor FC, Casas JP, et al. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med 2014 ; 12 : 51. [CrossRef] [PubMed] [Google Scholar]
  4. Maki KC, Ridker PM, Brown WV, et al. An assessment by the Statin Diabetes Safety Task Force: 2014 update. J Clin Lipidol 2014 ; 8 : 17–29. [CrossRef] [Google Scholar]
  5. Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol 2013 ; 29 : 1553–1568. [CrossRef] [PubMed] [Google Scholar]
  6. Mansi I, Frei CR, Pugh MJ, et al. Statins and musculoskeletal conditions, arthropathies, and injuries. JAMA Intern Med 2013 ; 173 : 1318–1326. [CrossRef] [PubMed] [Google Scholar]
  7. Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 2014 ; 8 (suppl 3) : S8–71. [CrossRef] [Google Scholar]
  8. Thompson PD, Parker B. Statins, exercise, and exercise training. J Am Coll Cardiol 2013 ; 62 : 715–716. [CrossRef] [PubMed] [Google Scholar]
  9. Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation 2013 ; 127 : 96–103. [CrossRef] [PubMed] [Google Scholar]
  10. Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J 2014 ; 168 : 6–15. [CrossRef] [PubMed] [Google Scholar]
  11. Finegold JA, Manisty CH, Goldacre B, et al. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol 2014 ; 21 : 464–474. [CrossRef] [PubMed] [Google Scholar]
  12. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study. Cardiovasc Drugs Ther 2005 ; 19 : 403–414. [CrossRef] [PubMed] [Google Scholar]
  13. Di Stasi SL, MacLeod TD, Winters JD, Binder-Macleod SA. Effects of statins on skeletal muscle: a perspective for physical therapists. Phys Ther 2010 ; 90 : 1530–1542. [CrossRef] [PubMed] [Google Scholar]
  14. Sinzinger H, O’Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 2004 ; 57 : 525–528. [CrossRef] [PubMed] [Google Scholar]
  15. Riechmann SE, Andrews RD, MacLean DA, Sheather S. Statins and dietary and serum cholesterol are associated with increased lean mass following resistance training. J Gerontol Biol Sci Med Sci 2007 ; 62 : 1164–1171. [CrossRef] [Google Scholar]
  16. Panayiotou G, Paschalis V, Nikolaidis MG, et al. No adverse effects of statins on muscle function and health-related parameters in the elderly: an exercise study. Scand J Med Sci Sports 2013 ; 23 : 556–567. [PubMed] [Google Scholar]
  17. Murlastis Z, Radak Z. The effects of statin medications on aerobic exercise capacity and training tdaptations. Sports Med 2014 ; 44 : 1519–1530. [CrossRef] [PubMed] [Google Scholar]
  18. Meador BM, Huey KA. Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve 2010 ; 42 : 469–479. [CrossRef] [PubMed] [Google Scholar]
  19. Mikus CR, Boyle LJ, Borengasser SJ, et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol 2013 ; 62 : 709–714. [CrossRef] [PubMed] [Google Scholar]
  20. Rengo JL, Savage PD, Toth MJ, Ades PA. Statin therapy does not attenuate exercise training response in cardiac rehabilitation. J Am Coll Cardiol 2014 ; 63 : 2050–2055. [CrossRef] [PubMed] [Google Scholar]
  21. Morandi A, Girard TD, Shintani A, et al. Association between statin use at admission to inpatient rehabilitation and functional status at discharge among older patients. Rejuvenation Res 2014 ; 17 : 490–495. [CrossRef] [PubMed] [Google Scholar]
  22. Bitzur R, Cohen H, Kamari Y, Harats D. Intolerance to statins: mechanisms and management. Diabetes Care 2013 ; 36 : 325–330. [CrossRef] [Google Scholar]
  23. Taha DA, De Moor CH, Barrett DA, Gershkovich P. Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies. Transl Res 2014 ; 164 : 85–109. [CrossRef] [Google Scholar]
  24. Moßhammer D, Schaeffeler E, Schwab M, Mörike K. Mechanisms and assessment of statin-related muscular adverse affects. Br J Clin Pharmacol 2014 ; 78 : 454–466. [CrossRef] [PubMed] [Google Scholar]
  25. Postmus I, Trompet S, Deshmukh HA, et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun 2014 ; 5 : 5068. [CrossRef] [PubMed] [Google Scholar]
  26. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 2014 ; 63 : 2935–2959. [CrossRef] [PubMed] [Google Scholar]
  27. DeGorter MK, Tirona RG, Schwarz UI, et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet 2013 ; 6 : 400–408. [CrossRef] [PubMed] [Google Scholar]
  28. Search Collaborative Group, Link E, Parish S, et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med 2008 ; 359 : 789–799. [CrossRef] [PubMed] [Google Scholar]
  29. Needham M, Mastaglia FL. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord 2014 ; 24 : 4–15. [CrossRef] [PubMed] [Google Scholar]
  30. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013 ; 368 : 1279–1290. [CrossRef] [PubMed] [Google Scholar]
  31. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy - European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Hearth J 2015 ; 36 : 1012–1022. [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.